BioAge Labs, Inc. (NASDAQ:BIOA) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Shares of BioAge Labs, Inc. (NASDAQ:BIOA) have been given an average recommendation of “Moderate Buy” by the eight ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $33.00.

A number of equities research analysts have issued reports on BIOA shares. BTIG Research reaffirmed a “buy” rating and issued a $40.00 price target on shares of BioAge Labs in a research report on Tuesday, September 8th. Weiss Ratings upgraded shares of BioAge Labs from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, October 26th. UBS Group started coverage on shares of BioAge Labs in a report on Sunday, October 11th. They issued a “neutral” rating and a $8.00 target price on the stock. Roth Capital reiterated a “buy” rating and issued a $25.00 price target on shares of BioAge Labs in a research note on Wednesday, September 9th. Finally, Wall Street Zen downgraded shares of BioAge Labs from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 10th.

BioAge Labs Price Performance

NASDAQ:BIOA opened at $5.87 on Monday. The company has a fifty day simple moving average of $7.39 and a two-hundred day simple moving average of $15.87. The company has a market cap of $269.42 million, a price-to-earnings ratio of -2.47 and a beta of 1.08. BioAge Labs has a 52 week low of $4.81 and a 52 week high of $25.95.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.07. The business had revenue of $2.45 million for the quarter. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%. On average, analysts expect that BioAge Labs will post -2.49 EPS for the current year.

Institutional Investors Weigh In On BioAge Labs

Hedge funds and other institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP purchased a new position in shares of BioAge Labs in the 1st quarter valued at about $3,746,000. Renaissance Technologies LLC lifted its stake in BioAge Labs by 653.2% during the first quarter. Renaissance Technologies LLC now owns 138,588 shares of the company’s stock worth $2,424,000 after purchasing an additional 120,188 shares during the last quarter. Stempoint Capital LP purchased a new stake in BioAge Labs during the first quarter worth approximately $5,923,000. Bank of America Corp DE acquired a new position in BioAge Labs in the second quarter valued at approximately $6,320,000. Finally, Walleye Capital LLC acquired a new position in BioAge Labs in the second quarter valued at approximately $8,686,000.

BioAge Labs Company Profile

BioAge Labs, Inc is a clinical-stage biotechnology company focused on developing medicines that target the biological mechanisms of aging. The company seeks to address diseases associated with aging by identifying therapeutic targets linked to human longevity and translating those discoveries into drug candidates.

BioAge uses large human data sets, computational biology, and machine-learning tools to study the molecular factors that influence healthy aging and age-related disease. Its research has produced a pipeline of investigational therapies, including azelaprag (BGE-105), an apelin receptor agonist being evaluated for potential applications involving metabolic health, body composition, and physical function.

Founded in 2015, BioAge is headquartered in Richmond, California, and conducts research and clinical development activities through collaborations and studies involving patients and research sites in multiple regions.